LJPC · La Jolla Pharmaceutical Co - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10.54M | $10.43M | - | $13.31M | $16.06M | $34.14M | - | $9.07M | $5.80M | $7.59M |
| Cost of Revenue | - | - | - | - | - | - | - | $2.49M | $808.0K | $716.0K |
| Gross Profit | - | - | - | - | - | - | - | $6.58M | $5.00M | $6.88M |
| R&D | $154.0K | $27.0K | - | $1.28M | $1.11M | $1.56M | - | $3.62M | $8.78M | $9.18M |
| SG&A | $9.76M | $10.27M | - | $8.63M | $9.00M | $8.76M | - | $12.49M | $8.68M | $8.15M |
| Total Operating Expenses | $11.61M | $12.47M | - | $12.79M | $12.27M | $16.64M | - | $18.60M | $18.27M | $18.05M |
| D&A | - | $25.0K | - | - | - | $29.0K | - | - | - | $1.06M |
| Operating Income | ($1.07M) | ($2.05M) | - | $525.0K | $3.79M | $17.49M | - | ($9.53M) | ($12.46M) | ($10.46M) |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $17.0K | $1.0K | - | $31.0K | $0 | $0 | - | - | - | - |
| Net Income | $2.46M | $2.0K | - | ($2.26M) | $3.73M | $14.42M | - | ($11.76M) | ($15.59M) | ($8.59M) |
| EPS - Basic | $0.10 | $0.00 | - | ($0.08) | $0.14 | ($0.32) | - | - | - | - |
| EPS - Diluted | $0.08 | $0.00 | - | ($0.08) | $0.11 | ($0.32) | - | - | - | - |
Balance Sheet
| Line item | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $48.34M | $44.17M | $46.67M | $46.77M | $45.89M | $38.63M | $21.22M | $27.76M | $68.35M | $77.22M |
| Accounts Receivable | $5.93M | $5.73M | $8.61M | $8.79M | $8.60M | $4.15M | $5.83M | $3.93M | $1.84M | $3.55M |
| Inventory | $8.30M | $7.11M | $6.28M | $6.09M | $5.48M | $5.37M | $6.01M | $7.27M | $3.12M | $1.96M |
| Accounts Payable | $2.13M | $2.79M | $2.28M | $2.31M | $1.85M | $1.10M | $2.76M | $3.93M | $2.48M | $1.90M |
| Current Assets | $66.36M | $62.92M | $67.31M | $65.92M | $65.17M | $54.27M | $36.46M | $42.20M | $79.17M | $86.11M |
| Total Assets | $99.37M | $96.38M | $101.23M | $100.29M | $100.01M | $89.59M | $72.24M | $80.72M | $107.39M | $118.21M |
| Current Liabilities | $16.49M | $16.05M | $17.64M | $15.99M | $16.10M | $11.71M | $12.34M | $18.76M | $17.88M | $16.05M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $168.83M | $166.87M | $167.97M | $168.70M | $167.45M | $161.91M | $160.33M | $166.24M | $182.61M | $179.88M |
| Stockholders' Equity | ($69.47M) | ($70.49M) | ($66.74M) | ($68.41M) | ($67.44M) | ($72.32M) | ($88.09M) | ($85.52M) | ($75.21M) | ($61.67M) |
| Retained Earnings | ($1.05B) | ($1.06B) | ($1.06B) | ($1.06B) | ($1.06B) | ($1.06B) | ($1.08B) | ($1.07B) | ($1.06B) | ($1.05B) |
Cash Flow
| Line item | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | $2.52M | - | - | - | $17.18M | - | - | - | ($12.25M) |
| Investing Cash Flow | - | - | - | - | - | - | - | - | - | $1.14M |
| Financing Cash Flow | - | ($5.02M) | - | - | - | $235.0K | - | - | - | $505.0K |
| CapEx | - | - | - | - | - | - | - | - | - | $0 |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | ($12.25M) |
Ratios
| Metric | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | 72.6% | 86.1% | 90.6% |
| Operating margin | -10.1% | -19.6% | - | 3.9% | 23.6% | 51.2% | - | -105.0% | -214.7% | -137.8% |
| EBITDA margin | - | -19.4% | - | - | - | 51.3% | - | - | - | -123.8% |
| Net margin | 23.3% | 0.0% | - | -17.0% | 23.2% | 42.2% | - | -129.6% | -268.6% | -113.2% |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | -161.4% |
| FCF / Net income | - | - | - | - | - | - | - | - | - | 1.43 |
| R&D / Revenue | 1.5% | 0.3% | - | 9.7% | 6.9% | 4.6% | - | 39.9% | 151.3% | 121.0% |
| SG&A / Revenue | 92.6% | 98.6% | - | 64.8% | 56.0% | 25.6% | - | 137.7% | 149.5% | 107.4% |
| Effective tax rate | 0.7% | 33.3% | - | - | 0.0% | 0.0% | - | - | - | - |
| Return on assets | 2.5% | 0.0% | - | -2.3% | 3.7% | 16.1% | - | -14.6% | -14.5% | -7.3% |
| Return on equity | -3.5% | -0.0% | - | 3.3% | -5.5% | -19.9% | - | 13.8% | 20.7% | 13.9% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 4.02 | 3.92 | 3.82 | 4.12 | 4.05 | 4.63 | 2.95 | 2.25 | 4.43 | 5.37 |
| Quick ratio | 3.52 | 3.48 | 3.46 | 3.74 | 3.71 | 4.18 | 2.47 | 1.86 | 4.25 | 5.24 |
| Cash ratio | 2.93 | 2.75 | 2.65 | 2.92 | 2.85 | 3.30 | 1.72 | 1.48 | 3.82 | 4.81 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | -1.43 | -1.37 | -1.52 | -1.47 | -1.48 | -1.24 | -0.82 | -0.94 | -1.43 | -1.92 |
| Liabilities / Assets | 1.70 | 1.73 | 1.66 | 1.68 | 1.67 | 1.81 | 2.22 | 2.06 | 1.70 | 1.52 |
| Efficiency | ||||||||||
| Asset turnover | 0.11 | 0.11 | - | 0.13 | 0.16 | 0.38 | - | 0.11 | 0.05 | 0.06 |
| Inventory turnover | - | - | - | - | - | - | - | 0.34 | 0.26 | 0.37 |
| Days sales outstanding | 205d | 201d | - | 241d | 195d | 44d | - | 158d | 116d | 171d |
| Days inventory outstanding | - | - | - | - | - | - | - | 1067d | 1409d | 999d |
| Days payable outstanding | - | - | - | - | - | - | - | 576d | 1121d | 966d |
| Cash conversion cycle | - | - | - | - | - | - | - | 649d | 405d | 204d |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -34.3% | -69.5% | - | 46.8% | 176.6% | 349.7% | - | 59.0% | 1.8% | 72.7% |
| Revenue CAGR (3y) | 22.7% | 33.4% | - | 56.6% | 116.0% | 248.1% | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | 213.5% | 129.4% | 170.9% | - | 69.6% | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | 27.8% | -3.0% | 76.5% |
| Operating income growth (YoY) | - | - | - | - | - | - | - | 64.5% | 55.8% | 64.7% |
| Net income growth (YoY) | -34.2% | -100.0% | - | 80.8% | - | - | - | 59.7% | 48.7% | 72.9% |
| EPS growth (YoY) | -27.3% | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | 62.7% |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -3.0% | 2.5% | 24.2% | 20.0% | 10.3% | -17.3% | -57.3% | -143.1% | -497.3% | - |
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing LA JOLLA PHARMACEUTICAL CO against the 5 most active filers in the same SIC group.